The FDA has approved Amgen Inc.’s (AMGN) IMLYGIC for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
Forex – financial instrument.Forex news
The FDA has approved Amgen Inc.’s (AMGN) IMLYGIC for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.